---
title: "NervGen Pharma Corp. (NGEN.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/NGEN.US.md"
symbol: "NGEN.US"
name: "NervGen Pharma Corp."
industry: "制药"
---

# NervGen Pharma Corp. (NGEN.US)

| Item | Detail |
|------|--------|
| Industry | 制药 |
| Location | 美股市场 |
| Website | [www.nervgen.com](https://www.nervgen.com) |

## Company Profile

NervGen Pharma Corp.是一家生物技术公司，专注于发现、开发和商业化药物治疗，以促进神经系统在神经创伤和神经疾病环境中的修复。该公司的主要产品候选药物是 NVG-291，目前正在进行针对脊髓损伤（SCI）、中风、多发性硬化症和阿尔茨海默病的 1b/2a 期临床试验；以及 NVG-300，正在进行缺血性中风的临床前模型和确认性 SCI 研究。NervGen Pharma Corp.与凯斯西储大学签订了许可协议，以开发和商业化一种具有治疗潜力的专利技术，适用于脊髓损伤及其他与神经损伤相关的疾病

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -18.41 | 202/257 | - | - | - |
| PB | -158.19 | 228/257 | - | - | - |
| Dividend Yield | 0.00% | - | - | - | - |

## References

- [Company Overview](https://longbridge.com/en/quote/NGEN.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/NGEN.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/NGEN.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.